1. Manaʻo ʻia e hoʻomaikaʻi i ka pilikia o ka hōʻino ʻana o ka puʻupaʻa a me ka make mai ka maʻi kīkī
Ua hoʻopuka ka hui ʻo WuXi AppTec ʻo Medical New Vision i ka nūhou e hōʻike ana i kahi noiʻi o 10,000 poʻe i hōʻike ʻia e hiki i ka metformin ke hoʻomaikaʻi i ka pilikia o ka hōʻino ʻana o ka puʻupaʻa a me ka make ʻana mai ka maʻi kīkī.
Ua hōʻike ʻia kahi haʻawina i paʻi ʻia ma ka puke pai ʻo American Diabetes Association (ADA) "Diabetes Care" (Diabetes Care) i ka lāʻau lapaʻau a me ke ola ʻana o ka ʻoi aku ma mua o 10,000 poʻe i hōʻike i nā mea maʻi maʻi diabetes type 2 me ka maʻi maʻi maʻi maʻi (CKD) lawe Metformin pili me ka emi ʻana o ka hopena o ka make a me ka maʻi renal hope (ESRD), a ʻaʻole e hoʻonui i ka hopena o ka lactic acidosis.
ʻO ka maʻi maʻi maʻi maʻamau ka hopena maʻamau o ka maʻi diabetes.I ka noʻonoʻo ʻana e hiki ke kuhikuhi ʻia nā mea maʻi me ka maʻi maʻi ʻāʻī i ka metformin, ua noiʻi ka hui noiʻi i nā maʻi 2704 i kēlā me kēia o nā hui ʻelua e lawe ana i ka metformin a ʻaʻole i lawe i ka metformin.
Ua hōʻike ʻia nā hopena i hoʻohālikelike ʻia me ka poʻe i lawe ʻole i ka metformin, ʻo ka poʻe maʻi i lawe i ka metformin he 35% ka emi ʻana o ka hopena o nā kumu āpau a me ka hōʻemi ʻana o 33% i ka piʻi ʻana i ka maʻi renal hope.Ua puka mālie kēia mau pōmaikaʻi ma hope o 2.5 mau makahiki o ka lawe ʻana i ka metformin.
Wahi a ka hōʻike, i nā makahiki i hala iho nei, ua ʻōlelo nā alakaʻi a ka US FDA i ka hoʻomaha ʻana i ka hoʻohana ʻana i ka metformin i nā poʻe maʻi me ka maʻi diabetes type 2 me ka maʻi maʻi maʻi maʻi, akā i nā mea maʻi me ka maʻi maʻi ʻeha.No nā poʻe maʻi me ka maʻi haʻahaʻa (pae 3B) a me ka maʻi maʻi maʻi maʻi maʻi, hoʻopaʻapaʻa mau ka hoʻohana ʻana i ka metformin.
Ua ʻōlelo ʻo Kauka Katherine R. Tuttle, he polopeka ma ke Kulanui o Wakinekona i ʻAmelika Hui Pū ʻIa: “He mea hōʻoluʻolu nā hopena o ka noiʻi.ʻOiai i nā poʻe maʻi me ka maʻi ʻeha koʻikoʻi, haʻahaʻa loa ka pilikia o ka lactic acidosis.No nā poʻe maʻi me ka maʻi maʻi type 2 a me ka maʻi maʻi maʻi maʻi, ʻo ka metformin ka mea e pale ai i ka make a me kahi lāʻau koʻikoʻi no ka hōʻino ʻole ʻana, akā no ka mea he haʻawina retrospective a nānā ʻia kēia, pono e wehewehe pono ʻia nā hopena.
2. ʻO nā mea lapaʻau like ʻole o ka metformin lāʻau kilokilo
Hiki ke ʻōlelo ʻia ʻo Metformin he lāʻau lapaʻau kahiko kahiko i lōʻihi loa.I ka piʻi ʻana o ka noiʻi lāʻau hypoglycemic, i ka makahiki 1957, ua paʻi ka ʻepekema Farani ʻo Stern i kāna mau hopena noiʻi a hoʻohui i ka ʻāpana lilac i loaʻa ka hana hypoglycemic i ka pī kao.Alkali, kapa ʻia ʻo metformin, Glucophage, ʻo ia hoʻi ka mea ʻai kō.
I ka makahiki 1994, ua ʻae ʻia ka metformin e ka US FDA no ka hoʻohana ʻana i ka maʻi diabetes type 2.ʻO Metformin, ʻo ia ka lāʻau lapaʻau mana no ka mālama ʻana i ka maʻi diabetes type 2, ua helu ʻia ma ke ʻano he lāʻau lapaʻau hypoglycemic mua i nā ʻano alakaʻi lapaʻau ma ka home a ma waho.Loaʻa iā ia nā pōmaikaʻi o ka hopena hypoglycemic pololei, haʻahaʻa haʻahaʻa o ka hypoglycemia, a me ke kumu kūʻai haʻahaʻa.ʻO ia ka lāʻau lapaʻau i hoʻohana nui ʻia ʻO kekahi o ka papa o nā lāʻau hypoglycemic.
Ma ke ʻano he lāʻau lapaʻau i hoʻāʻo ʻia i ka manawa, ua manaʻo ʻia aia ma mua o 120 miliona mau mea hoʻohana o ka metformin ma ka honua holoʻokoʻa.
Me ka hohonu o ka noiʻi ʻana, ua hoʻonui mau ʻia ka therapeutic hiki o ka metformin.Ma kahi o nā mea i ʻike hou ʻia, ua ʻike ʻia ʻo ka metformin ma kahi o 20 mau hopena.
1. Ka hopena anti-kahiko
I kēia manawa, ua ʻae ka US Food and Drug Administration i ka hoʻokolohua lapaʻau o ka "hoʻohana ʻana i ka metformin e hakakā i ka ʻelemakule".ʻO ke kumu o ka hoʻohana ʻana o nā ʻepekema haole i ka metformin ma ke ʻano he moho lāʻau anti-aging no ka mea hiki i ka metformin ke hoʻonui i ka nui o nā molekala oxygen i hoʻokuʻu ʻia i loko o nā cell.Ma luna o nā mea a pau, ʻo ia ka mea e hoʻonui ai i ka pono o ke kino a hoʻolōʻihi i ke ola.
2. Hoʻemi kaumaha
ʻO Metformin kahi lāʻau hypoglycemic hiki ke lilo i ke kaumaha.Hiki iā ia ke hoʻonui i ka naʻau o ka insulin a hoʻemi i ka synthesis momona.No ka poʻe makemake i ke kōpaʻa ʻano 2, ʻo ka lilo ʻana o ke kaumaha he mea kūpono ia i ka hoʻokele paʻa o ke kō koko.
Ua hōʻike ʻia kahi noiʻi a ka hui noiʻi ʻo United States Diabetes Prevention Program (DPP) i loko o kahi manawa noiʻi ʻole o 7-8 mau makahiki, ua nalowale nā mea maʻi i loaʻa i ka lāʻau metformin i ka awelika o 3.1 kg o ke kaumaha.
3. E ho'ēmi i ka pilikia o ka hāʻule ʻana a me ka hānau mua ʻana no kekahi mau wāhine hāpai
Hōʻike ka noiʻi hou loa i paʻi ʻia ma The Lancet e hiki i ka metformin ke hōʻemi i ka hopena o ka hāʻule ʻana a me ka hānau mua ʻana i kekahi mau wahine hāpai.
Wahi a nā hōʻike, ua hana nā kānaka ʻepekema mai ke Kulanui o ʻEpekema a me ʻenehana (NTNU) a me St. Olavs Hospital i kahi noiʻi kokoke i 20 mau makahiki a ʻike ʻia nā mea maʻi me ka polycystic ovary syndrome e lawe ana i ka metformin i ka pau ʻana o 3 mau mahina o ka hāpai ʻana e hōʻemi i ka post- manawa hāʻule a me ka hāʻule ʻole.Ka pilikia o ka hānau hānau ʻana.
4. Kāohi i ka ʻaʻa i hana ʻia e ka smog
Ua hōʻike nā hopena o ke aʻo ʻana ua hōʻoia ka hui i alakaʻi ʻia e Profesor Scott Budinger o ke Kulanui o Northwestern i nā ʻiole e hiki i ka metformin ke pale i ka mumū i hoʻokumu ʻia e ka smog, pale i nā cell immune mai ka hoʻokuʻu ʻana i kahi mole pōʻino i loko o ke koko, ke kāohi i ka hoʻokumu ʻana o ka thrombosis arterial, a no laila. hōʻemi i ka ʻōnaehana cardiovascular.ʻO ka pilikia o ka maʻi.
5. Ka pale ʻana i ka maʻi cardiovascular
Loaʻa ka Metformin i nā hopena pale cardiovascular a ʻo ia wale nō ka lāʻau hypoglycemic i ʻōlelo ʻia e nā alakaʻi maʻi diabetes me ka loaʻa ʻana o nā hōʻike maopopo o ka pono cardiovascular.Ua hōʻike ʻia nā haʻawina e pili ana ka mālama lōʻihi o ka metformin i ka emi ʻana o ka pilikia o ka maʻi cardiovascular i nā maʻi maʻi maʻi type 2 hou a me nā maʻi maʻi maʻi type 2 i hoʻomohala mua i ka maʻi cardiovascular.
6. Hoʻonui i ka polycystic ovary syndrome
ʻO ka Polycystic ovary syndrome kahi maʻi heterogeneous i hōʻike ʻia e ka hyperandrogenemia, ovarian dysfunction, a me polycystic ovary morphology.ʻAʻole maopopo kona pathogenesis, a loaʻa pinepine nā maʻi i nā pae like ʻole o ka hyperinsulinemia.Ua hōʻike nā haʻawina e hiki i ka metformin ke hōʻemi i ka pale ʻana o ka insulin, hoʻihoʻi i kāna hana ovulation, a hoʻomaikaʻi i ka hyperandrogenemia.
7. Hoʻomaikaʻi i ka flora ʻōpū
Ua hōʻike ʻia nā haʻawina e hiki i ka metformin ke hoʻihoʻi i ka hapa o ka flora intestinal a hoʻololi iā ia i kahi ala kūpono i ke olakino.Hāʻawi ia i kahi nohona maikaʻi no ka bacteria maikaʻi i loko o ka ʻōpū, a laila e hoʻohaʻahaʻa i ke kō koko a hoʻoponopono maikaʻi i ka ʻōnaehana pale.
8. Manaʻo ʻia e mālama i kekahi autism
I kēia mau lā, ua ʻike nā mea noiʻi ma ke Kulanui ʻo McGill e hiki i ka metformin ke mālama i kekahi mau ʻano o ka maʻi Fragile X me ka autism, a ua paʻi ʻia kēia noiʻi hou ma ka puke pai Nature Medicine, kahi sub-issue o Nature.I kēia manawa, ʻo ka autism kekahi o nā maʻi lapaʻau i manaʻoʻiʻo ʻia e nā ʻepekema hiki ke mālama ʻia me ka metformin.
9. Reverse pulmonary fibrosis
Ua ʻike nā mea noiʻi ma ke Kulanui o Alabama ma Birmingham i nā poʻe maʻi me ka idiopathic pulmonary fibrosis a me nā hiʻohiʻona pulmonary fibrosis ʻiole i hoʻokomo ʻia e bleomycin, ua hoʻemi ʻia ka hana o AMPK i loko o nā ʻiʻo fibrotic, a me nā ʻiʻo e kūʻē i nā cell Ua piʻi ka apoptotic myofibroblasts.
ʻO ka hoʻohana ʻana i ka metformin e hoʻāla i ka AMPK i ka myofibroblasts hiki ke hoʻihoʻi hou i kēia mau cell i ka apoptosis.Eia kekahi, ma ke ʻano ʻiole, hiki i ka metformin ke hoʻolalelale i ka ablation o ka ʻiʻo fibrotic i hana mua ʻia.Hōʻike kēia haʻawina e hiki ke hoʻohana ʻia ka metformin a i ʻole nā agonists AMPK e hoʻohuli i ka fibrosis i hana mua ʻia.
10. Kōkua i ka haʻalele ʻana i ka puhi paka
Ua ʻike nā mea noiʻi ma ke Kulanui o Pennsylvania e hiki i ka hoʻohana ʻana i ka nicotine lōʻihi ke alakaʻi i ka hoʻāla ʻana o ke ala hōʻailona AMPK, i kāohi ʻia i ka wā o ka haʻalele ʻana i ka nicotine.No laila, ua hoʻoholo lākou inā hoʻohana ʻia nā lāʻau lapaʻau e hoʻāla i ke ala hōʻailona AMPK, hiki ke hoʻohaʻahaʻa i ka pane haʻalele.
ʻO Metformin kahi agonist AMPK.I ka hāʻawi ʻana o ka poʻe noiʻi i ka metformin i nā ʻiole i haʻalele i ka nicotine, ua ʻike lākou ua hoʻomaha ia i ka haʻalele ʻana o nā ʻiole.Hōʻike kā lākou noiʻi hiki ke hoʻohana ʻia ka metformin e kōkua i ka haʻalele ʻana i ka ulaula.
11. Ka hopena anti-inflammatory
Ma mua, ua hōʻike ʻia nā haʻawina preclinical a me nā lāʻau lapaʻau ʻaʻole hiki i ka metformin ke hoʻomaikaʻi wale i ka maʻi ʻeha ma o ka hoʻomaikaʻi ʻana i nā ʻāpana metabolic e like me hyperglycemia, insulin resistance a me atherosclerotic dyslipidemia, akā loaʻa pū kekahi hopena anti-inflammatory.
Ua hōʻike ʻia nā haʻawina e hiki i ka metformin ke pale i ka mumū, ʻoi loa ma o ka AMP-activated protein kinase (AMPK) -depende a i ʻole ka pale kūʻokoʻa o ka nuclear transcription factor B (NFB).
12. Hoʻohuli i ka hoʻohaʻahaʻa naʻau
Ua hana nā mea noiʻi ma ke Kulanui o Texas ma Dallas i kahi kiʻi ʻiole e hoʻohālike ana i ka hōʻino ʻana i ka ʻeha.Ua hoʻohana lākou i kēia ʻano hoʻohālike e hoʻāʻo i ka pono o nā lāʻau he nui.
Hōʻike nā hopena hoʻokolohua ʻo ka mālama ʻana i nā ʻiole me 200 mg/kg ke kaumaha o ke kino o ka metformin no 7 mau lā hiki ke hoʻohuli loa i ka pōʻino o ka naʻau ma muli o ka ʻeha.
ʻO Gabapentin, ka mea mālama i ka neuralgia a me ka epilepsy, ʻaʻohe hopena like.ʻO ia ke ʻano hiki ke hoʻohana ʻia ka metformin ma ke ʻano he lāʻau lapaʻau kahiko e mālama ai i ka hōʻino cognitive i nā maʻi me ka neuralgia.
13. Kāohi i ka ulu ʻana o ke koko
I kekahi mau lā i hala aku nei, e like me Singularity.com, ua ʻike nā loea mai ka European Institute of Oncology e hiki i ka metformin a me ka hoʻokē ʻai ke hana synergistically e pale i ka ulu ʻana o nā ʻiole.
Ma o ka noiʻi hou aʻe, ua ʻike ʻia ʻo ka metformin a me ka hoʻokē ʻai ʻana ke kāohi i ka ulu ʻana o ka maʻi maʻi ma o ke ala PP2A-GSK3β-MCL-1.Ua paʻi ʻia ka noiʻi ma Cancer Cell.
14. Hiki ke pale i ka macular degeneration
Ua ʻike ʻo Kauka Yu-Yen Chen mai Taichung Veterans General Hospital ma Taiwan, Kina, ʻoi aku ka haʻahaʻa o ka maʻi macular degeneration (AMD) pili i ka makahiki i nā maʻi me ka maʻi diabetes type 2 e lawe ana i ka metformin.Hōʻike kēia i ka mālama ʻana i ka maʻi diabetes, ʻo nā hana anti-inflammatory a antioxidant o ka metformin he hopena pale i ka AMD.
15. A i ʻole hiki ke mālama i ka lauoho lauoho
Ua ʻike ka hui o Huang Jing, he kanaka ʻepekema Kina ma ke Kulanui o Kaleponi, Los Angeles, hiki i nā lāʻau lapaʻau e like me ka metformin a me ka rapamycin ke hoʻoulu i nā follicles lauoho i ka manawa hoʻomaha o nā ʻiole e komo i ka wā ulu a hoʻoikaika i ka ulu lauoho.Ua paʻi ʻia nā noiʻi pili i loko o ka puke moʻolelo kaulana ʻo Cell Reports.
Eia kekahi, i ka wā i hoʻohana ai nā ʻepekema i ka metformin e mālama i nā poʻe maʻi me ka polycystic ovary syndrome ma Kina a me India, ua ʻike pū lākou ua pili ka metformin me ka emi ʻana o ka lauoho.
16. Hoʻohuli i nā makahiki olaola
ʻO ka mea i hala koke nei, ua paʻi ka pūnaewele mana o ka nūpepa ʻepekema a me ka ʻenehana honua "Nature" i kahi nūhou blockbuster.Hōʻike nā hōʻike i kahi noiʻi liʻiliʻi liʻiliʻi ma Kaleponi i hōʻike no ka manawa mua e hiki ke hoʻohuli i ka uaki epigenetic kanaka.I ka makahiki i hala, ʻeiwa mau mea manawaleʻa olakino i lawe i ka hui ʻana o ka hormone ulu a me ʻelua mau lāʻau maʻi diabetes, me ka metformin.Ana ʻia ma ka nānā ʻana i nā māka ma ka genome o ke kanaka, ua emi ko lākou mau makahiki olaola ma ka awelika o 2.5 mau makahiki.
17. Hiki i ka lā'au hui ke mālama i ka ma'i ma'i umauma triple-negative
I kekahi mau lā i hala aku nei, ua ʻike kahi hui i alakaʻi ʻia e Kauka Marsha rich rosner o ke Kulanui o Chicago ʻo ka hui pū ʻana o ka metformin a me kekahi lāʻau lapaʻau kahiko, heme (panhematin), hiki ke kuhikuhi i ka mālama ʻana i ka maʻi kanesa umauma triple-negative e hoʻoweliweli koʻikoʻi i ke olakino wahine. .
A aia nā hōʻike e hiki ai i kēia hoʻolālā lapaʻau ke kūpono no nā ʻano maʻi maʻi like ʻole e like me ka maʻi maʻi ʻāʻī, ka maʻi maʻi ʻaʻai, ka maʻi maʻi ʻōpū, ka maʻi prostate a me ka leukemia myeloid acute.Ua paʻi ʻia nā noiʻi pili ma ka puke pai ʻo Nature.
18. Hiki ke ho'ēmi i ka hopena o ka glucocorticoids
I kēia mau lā, ua paʻi ʻo "The Lancet-Diabetes and Endocrinology" i kahi noiʻi - ua hōʻike nā hopena o ka noiʻi i loko o kahi hoʻokolohua lapaʻau ʻo 2, hoʻohana ʻia ka metformin i nā mea maʻi me nā maʻi inflammatory mau hiki ke hoʻomaikaʻi i ke olakino metabolic a hōʻemi i ka mālama ʻana i ka glucocorticoid Nā hopena ʻaoʻao koʻikoʻi.
Ua hōʻike ʻia nā hoʻokolohua e hiki ke hana ʻo Metformin ma o ka key metabolic protein AMPK, a ʻo ke ʻano o ka hana ke kūʻē maoli i nā glucocorticoids, a hiki ke hoʻohuli i nā hopena ʻaoʻao i hoʻohana ʻia e ka hoʻohana nui ʻana i nā glucocorticoids.
19. Manaʻolana e mālama i ka sclerosis lehulehu
Ma mua, ua hoʻopuka kahi hui noiʻi i alakaʻi ʻia e Robin JM Franklin o ke Kulanui o Cambridge a me kāna haumāna ʻo Peter van Wijngaarden i kahi ʻatikala ma ka puke puke kiʻekiʻe "Cell Stem Cells" ua loaʻa iā lākou kahi ʻano kūikawā o nā pūnaewele neural ʻelemakule e hiki ke hoʻōla ma hope o ka mālama ʻana me Metformin.I ka pane ʻana i nā hōʻailona hoʻokaʻawale ʻokoʻa, ʻike hou ʻia ka ikaika o ka ʻōpio a hoʻoikaika hou i ka hana hou ʻana o ka myelin nerve.
ʻO kēia ʻike ka manaʻo e hoʻohana ʻia ka metformin i ka mālama ʻana i nā maʻi pili ʻole neurodegeneration, e like me ka maʻi sclerosis.
Ka manawa hoʻouna: Apr-21-2021